Yousuf Gaffar

880 total citations
9 papers, 218 citations indexed

About

Yousuf Gaffar is a scholar working on Molecular Biology, Hematology and Oncology. According to data from OpenAlex, Yousuf Gaffar has authored 9 papers receiving a total of 218 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Molecular Biology, 7 papers in Hematology and 5 papers in Oncology. Recurrent topics in Yousuf Gaffar's work include Multiple Myeloma Research and Treatments (7 papers), Protein Degradation and Inhibitors (6 papers) and Cancer Treatment and Pharmacology (2 papers). Yousuf Gaffar is often cited by papers focused on Multiple Myeloma Research and Treatments (7 papers), Protein Degradation and Inhibitors (6 papers) and Cancer Treatment and Pharmacology (2 papers). Yousuf Gaffar collaborates with scholars based in United States and United Kingdom. Yousuf Gaffar's co-authors include Ian W. Flinn, Rubén Niesvizky, Robert M. Rifkin, James A. Reeves, Veena Charu, Billy Clowney, James Essell, Nashat Gabrail, Liviu Niculescu and Yanyan Zhu and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Annals of Oncology.

In The Last Decade

Yousuf Gaffar

9 papers receiving 212 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Yousuf Gaffar United States	6	202	188	149	23	7	9	218
Billy Clowney United States	6	220 1.1×	173 0.9×	144 1.0×	27 1.2×	4 0.6×	7	233
Nicholas Pirooz United States	4	255 1.3×	222 1.2×	161 1.1×	22 1.0×	11 1.6×	7	276
S Caltagirone Italy	5	230 1.1×	219 1.2×	123 0.8×	15 0.7×	9 1.3×	11	251
Rianne Ammerlaan Netherlands	4	294 1.5×	247 1.3×	169 1.1×	21 0.9×	3 0.4×	6	302
Rafael Martínez-Martinez Mexico	4	191 0.9×	181 1.0×	118 0.8×	14 0.6×	3 0.4×	6	236
Claudia Polloni Italy	8	167 0.8×	136 0.7×	106 0.7×	22 1.0×	3 0.4×	16	189
Adrienne Briggs United States	5	191 0.9×	142 0.8×	118 0.8×	21 0.9×	14 2.0×	8	214
Olga Samoilova United States	2	296 1.5×	250 1.3×	192 1.3×	30 1.3×	10 1.4×	2	313
Ravi Vij United States	4	137 0.7×	117 0.6×	60 0.4×	11 0.5×	4 0.6×	13	171
Ashraf Elghandour Egypt	5	119 0.6×	133 0.7×	71 0.5×	6 0.3×	9 1.3×	11	174

Countries citing papers authored by Yousuf Gaffar

Since Specialization

Citations

This map shows the geographic impact of Yousuf Gaffar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yousuf Gaffar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yousuf Gaffar more than expected).

Fields of papers citing papers by Yousuf Gaffar

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yousuf Gaffar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yousuf Gaffar. The network helps show where Yousuf Gaffar may publish in the future.

Co-authorship network of co-authors of Yousuf Gaffar

This figure shows the co-authorship network connecting the top 25 collaborators of Yousuf Gaffar. A scholar is included among the top collaborators of Yousuf Gaffar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yousuf Gaffar. Yousuf Gaffar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

Ou, S-H.I., Alexander I. Spira, Pasi A. Jänne, et al.. (2023). 549O Adagrasib with or without cetuximab in patients with KRASG12C-mutated colorectal cancer (CRC): Analysis of tumor biomarkers and genomic alterations. Annals of Oncology. 34. S410–S410. 5 indexed citations

Niesvizky, Rubén, Ian W. Flinn, Robert M. Rifkin, et al.. (2015). Community-Based Phase IIIB Trial of Three UPFRONT Bortezomib-Based Myeloma Regimens. Journal of Clinical Oncology. 33(33). 3921–3929. 121 indexed citations

Niesvizky, Rubén, Ian W. Flinn, Robert M. Rifkin, et al.. (2013). Efficacy and Safety Of Three Bortezomib-Based Induction and Maintenance Regimens In Previously Untreated, Transplant-Ineligible Multiple Myeloma (MM) Patients (Pts): Final Results From The Randomized, Phase 3b, US Community-Based UPFRONT Study (NCT00507416). Blood. 122(21). 1966–1966. 12 indexed citations

Niesvizky, Rubén, Ian W. Flinn, N. Gabrail, et al.. (2011). Impact of baseline characteristics on efficacy and safety after bortezomib-based induction and maintenance in newly diagnosed multiple myeloma (MM) patients ineligible for transplant in the phase IIIb UPFRONT study.. Journal of Clinical Oncology. 29(15_suppl). 8072–8072. 1 indexed citations

Niesvizky, Rubén, Ian W. Flinn, Robert M. Rifkin, et al.. (2011). Efficacy and Safety of Three Bortezomib-Based Combinations in Elderly, Newly Diagnosed Multiple Myeloma Patients: Results From All Randomized Patients in the Community-Based, Phase 3b UPFRONT Study. Blood. 118(21). 478–478. 27 indexed citations

Niesvizky, Rubén, Ian W. Flinn, Robert M. Rifkin, et al.. (2011). Patient-Reported Quality of Life (QoL) in Elderly, Newly Diagnosed Multiple Myeloma (MM) Patients Receiving Bortezomib-Based Combinations: Results From All Randomized Patients in the Community-Based, Phase 3b UPFRONT Study. Blood. 118(21). 1864–1864. 18 indexed citations

Niesvizky, Rubén, Ian W. Flinn, Robert M. Rifkin, et al.. (2010). Patient-Reported Quality of Life In Elderly, Newly Diagnosed Multiple Myeloma Patients Treated with Bortezomib-Based Regimens: Results From the Phase 3b UPFRONT Study. Blood. 116(21). 3026–3026. 3 indexed citations

Niesvizky, Rubén, Ian W. Flinn, Robert M. Rifkin, et al.. (2010). Phase 3b UPFRONT Study: Safety and Efficacy of Weekly Bortezomib Maintenance Therapy After Bortezomib-Based Induction Regimens In Elderly, Newly Diagnosed Multiple Myeloma Patients. Blood. 116(21). 619–619. 27 indexed citations

Konduri, Kartik, Alexander I. Spira, Robert M. Jotte, et al.. (2009). Results from a phase I safety lead-in study investigating the combination of erlotinib and the histone deacetylase inhibitor entinostat in patients with advanced NSCLC. Journal of Clinical Oncology. 27(15_suppl). e14545–e14545. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact